Market Movers (8-K)
See all →OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. has completed the acquisition of six gold mineral properties in Canada through its subsidiary Maritimes Gold Corp., establishing net smelter returns royalty agreements with the vendors.
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. has completed the acquisition of Avid Gold Ltd and entered into an agreement to acquire Canadian gold properties, diversifying its business into gold exploration and development.
Capital raise
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. announced its entry into a Share Exchange Agreement to acquire 100% of Avid Gold Ltd., a UK-based private limited company, in a transaction valued at approximately $100,000 plus 4,500,000 shares of Series A Preferred Stock.
Capital raise
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. has terminated its acquisition agreement with YourSpace America, Inc. due to the failure of YourSpace to provide audited financial statements, leading to the resignation of the appointed CEO and the appointment of the Chairman as the new CEO.
Worse than expected
Delay expected
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. has finalized its merger with YourSpace America, Inc., resulting in a change of control and the appointment of William R. Russ Colvin as CEO.
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. has agreed to merge with YourSpace America, Inc. in a share exchange agreement, making YourSpace a wholly-owned subsidiary.
Quarterly Earnings (10-Q)
See all →OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. reports a strategic pivot towards gold exploration through acquisitions, while continuing to face significant financial headwinds and an uncertain going concern status.
Capital raise
Worse than expected
OQB
NUMD
Nu-med Plus, INCNU-MED PLUS, an early-stage medical device company, reported a net loss for Q3 2025 and expressed substantial doubt about its ability to continue as a going concern without significant new capital.
Delay expected
Worse than expected
Capital raise
OQB
NUMD
Nu-med Plus, INCNU-MED PLUS, an early-stage medical device company, reported a net loss and significant working capital deficiency, raising substantial doubt about its ability to continue operations without immediate capital infusion.
Delay expected
Worse than expected
Capital raise
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, a medical device company, reported no revenue and a net loss of $19,933 for the quarter ended March 31, 2025, highlighting the company's reliance on external funding to continue operations and product development.
Worse than expected
Capital raise
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. reported its third quarter 2024 results, showing no revenue and a net loss, while also announcing the termination of its merger agreement with YourSpace America, Inc.
Worse than expected
Delay expected
Capital raise
OQB
NUMD
Nu-med Plus, INCNu-Med Plus reports no revenue and a net loss for the second quarter of 2024, while awaiting the completion of the YourSpace America merger.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. files its annual report on Form 10-K for the fiscal year ended December 31, 2025, detailing its ongoing development of nitric oxide delivery systems and its precarious financial situation.
Delay expected
Worse than expected
Capital raise
OQB
NUMD
Nu-med Plus, INCNu-Med Plus, Inc. files its Form 10-K for the year ended December 31, 2024, reporting a net loss and highlighting substantial doubt about its ability to continue as a going concern without additional funding.
Delay expected
Worse than expected
Capital raise
OQB
NUMD
Nu-med Plus, INC10-K: Nu-Med Plus, Inc. Reports Annual Results for Fiscal Year 2023, Cites Going Concern Uncertainty
Nu-Med Plus, Inc. reports its 2023 annual results, highlighting ongoing product development challenges and a significant net loss, while also expressing substantial doubt about the company's ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
Insider Trading (Form 4)
OQB
NUMD
Nu-med Plus, INCFred Tejada, SVP and Chief Geologist, a Director and 10% owner of Nu-Med Plus, Inc., reported multiple transactions in common stock on July 8, 2026.
Schedule 13D - Activist Investments
OQB
NUMD
Nu-med Plus, INCFred Tejada has acquired substantial voting power over Nu-Med Plus, Inc. common stock through a series of strategic agreements and stock issuances, impacting corporate governance and future strategic direction.